Greenwood Capital Associates’s CRISPR Therapeutics CRSP Stock Holding History

Greenwood Capital Associates’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,733	Closed	-$265K	–	242
2024 Q4	$265K	Sell	6,733 -233	-3%	-$11K	0.03%	226
2024 Q3	$327K	Sell	6,966 -162	-2%	-$8.22K	0.04%	208
2024 Q2	$385K	Buy	7,128 +434	+6%	+$25.1K	0.05%	202
2024 Q1	$456K	Sell	6,694 -107	-2%	-$7.66K	0.06%	206
2023 Q4	$426K	Buy	6,801 +1,306	+24%	+$72.2K	0.06%	203
2023 Q3	$249K	Buy	5,495 +31	+0.6%	+$1.6K	0.04%	234
2023 Q2	$307K	Sell	5,464 -167	-3%	-$9.48K	0.04%	217
2023 Q1	$255K	Sell	5,631 -59,374	-91%	-$2.88M	0.04%	218
2022 Q4	$2.64M	Buy	65,005 +4,950	+8%	+$263K	0.43%	61
2022 Q3	$3.92M	Buy	+60,055	New	+$4.35M	0.67%	49

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Greenwood Capital Associates's CRSP Position: Q1 2025 in Review

Greenwood Capital Associates sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 6,733 shares — an estimated $265K sold.

Greenwood Capital Associates first reported a position in CRSP in Q3 2022 and held it in 10 quarters. The position peaked at $3.92M in Q3 2022. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

Greenwood Capital Associates reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
Greenwood Capital Associates sold 6,733 CRISPR Therapeutics shares in Q1 2025, an estimated $265K.
Greenwood Capital Associates first reported a position in CRISPR Therapeutics in Q3 2022 and held it in 10 quarters.
Greenwood Capital Associates's CRISPR Therapeutics position peaked at $3.92M in Q3 2022.
396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Greenwood Capital Associates's 13F filing for Q1 2025, filed 15 Apr 2025.